Precision Medicine Market Size to Hit USD 470.53 Bn by 2034

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global Precision Medicine Market, By Technology

7.1. Precision Medicine Market, by Technology Type
7.1.1. Bioinformatics
7.1.1.1. Market Revenue and Forecast
7.1.2. Big Data Analytics
7.1.2.1. Market Revenue and Forecast
7.1.3. Drug Discovery
7.1.3.1. Market Revenue and Forecast
7.1.4. Gene Sequencing
7.1.4.1. Market Revenue and Forecast
7.1.5. Companion Diagnostics
7.1.5.1. Market Revenue and Forecast
7.1.6. Others
7.1.6.1. Market Revenue and Forecast

Chapter 8. Global Precision Medicine Market, By Application

8.1. Precision Medicine Market, by Application
8.1.1. CNS
8.1.1.1. Market Revenue and Forecast
8.1.2. Immunology
8.1.2.1. Market Revenue and Forecast
8.1.3. Oncology
8.1.3.1. Market Revenue and Forecast
8.1.4. Respiratory
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast

Chapter 9. Global Precision Medicine Market, By End-Use

9.1. Precision Medicine Market, by End-Use
9.1.1. Diagnostic Companies
9.1.1.1. Market Revenue and Forecast
9.1.2. Pharmaceutical Companies
9.1.2.1. Market Revenue and Forecast
9.1.3. Healthcare IT companies
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast

Chapter 10. Global Precision Medicine Market, Regional Estimates and Trend Forecast

10.1. North America
10.1.1. Market Revenue and Forecast, by Technology
10.1.2. Market Revenue and Forecast, by Application
10.1.3. Market Revenue and Forecast, by End-Use
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Technology
10.1.4.2. Market Revenue and Forecast, by Application
10.1.4.3. Market Revenue and Forecast, by End-Use
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Technology
10.1.5.2. Market Revenue and Forecast, by Application
10.1.5.3. Market Revenue and Forecast, by End-Use
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology
10.2.2. Market Revenue and Forecast, by Application
10.2.3. Market Revenue and Forecast, by End-Use
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Technology
10.2.4.2. Market Revenue and Forecast, by Application
10.2.4.3. Market Revenue and Forecast, by End-Use
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Technology
10.2.5.2. Market Revenue and Forecast, by Application
10.2.5.3. Market Revenue and Forecast, by End-Use
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Technology
10.2.6.2. Market Revenue and Forecast, by Application
10.2.6.3. Market Revenue and Forecast, by End-Use
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Technology
10.2.7.2. Market Revenue and Forecast, by Application
10.2.7.3. Market Revenue and Forecast, by End-Use
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology
10.3.2. Market Revenue and Forecast, by Application
10.3.3. Market Revenue and Forecast, by End-Use
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Technology
10.3.4.2. Market Revenue and Forecast, by Application
10.3.4.3. Market Revenue and Forecast, by End-Use
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Technology
10.3.5.2. Market Revenue and Forecast, by Application
10.3.5.3. Market Revenue and Forecast, by End-Use
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Technology
10.3.6.2. Market Revenue and Forecast, by Application
10.3.6.3. Market Revenue and Forecast, by End-Use
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Technology
10.3.7.2. Market Revenue and Forecast, by Application
10.3.7.3. Market Revenue and Forecast, by End-Use
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology
10.4.2. Market Revenue and Forecast, by Application
10.4.3. Market Revenue and Forecast, by End-Use
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Technology
10.4.4.2. Market Revenue and Forecast, by Application
10.4.4.3. Market Revenue and Forecast, by End-Use
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Technology
10.4.5.2. Market Revenue and Forecast, by Application
10.4.5.3. Market Revenue and Forecast, by End-Use
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Technology
10.4.6.2. Market Revenue and Forecast, by Application
10.4.6.3. Market Revenue and Forecast, by End-Use
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Technology
10.4.7.2. Market Revenue and Forecast, by Application
10.4.7.3. Market Revenue and Forecast, by End-Use
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology
10.5.2. Market Revenue and Forecast, by Application
10.5.3. Market Revenue and Forecast, by End-Use
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Technology
10.5.4.2. Market Revenue and Forecast, by Application
10.5.4.3. Market Revenue and Forecast, by End-Use
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Technology
10.5.5.2. Market Revenue and Forecast, by Application
10.5.5.3. Market Revenue and Forecast, by End-Use

Chapter 11. Company Profiles

11.1. Biocrates Life Sciences
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Tepnel Pharma Services
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Novartis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Qiagen
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Quest Diagnostics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Menarini Silicon Biosystems
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. NanoString Technologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eagle Genomics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Pfizer
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Intomics
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Roche
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Teva Pharmaceutical
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global precision medicine market size valued at USD 119.03 billion in 2025 and is expected to reach USD 470.53 billion by 2034.

The global precision medicine market is poised to grow at a compound annual growth rate (CAGR) of 16.50% during the forecast period 2025 to 2034.

The advent of precision medicine has significantly brought a paradigm shift in the drug delivery and diagnosis of the disease. The proliferation of sequencing methodologies, particularly Next Generation Sequencing (NGS), due to the increasing cost of sequencing and development of the Human Genome Project in the field of genomics is predicted to drive the market.

North America dominated the global precision medicine market with revenue share of nearly 54% in 2025 and expected to grow at an escalating pace during the forecast period.

Some of the key players operating in the market are Biocrates Life Sciences, TepnelPharma Services, Novartis, Qiagen, Quest Diagnostics, Menarini Silicon Biosystems, NanoString Technologies, Eagle Genomics, Pfizer, Intomics, Roche, and Teva Pharmaceutical among others.

The Asia Pacific seeks lucrative growth over the forecast period due to low cost clinical trials of newly developed diagnostic products and precision medicine. Furthermore, rising disposable income and rising economy in the developing nations such as India expected to boost the demand of precision medicines in the region.

By technology, drug discovery registered considerable growth in the recent past and expect to lead the overall market revenue in 2024.

Oncology application led the global precision medicine market with significant revenue share in 2024 and analyzed to grow at a prominent rate during the forecast period.